Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.52 |
| ▸ | DRD3 | P35462 | 9/20 | 0.52 |
| ▸ | DRD2 | P14416 | 9/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395932 | 0.79 | DRD4 (0.67) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL6585625 | 0.76 | DRD4 (0.63) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL29188191 | 0.76 | DRD4 (0.67) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL2708167 | 0.75 | DRD4 (0.55) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL7964854 | 0.73 | GAA (0.52) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL8611543 | 0.73 | DRD4 (0.60) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL10374922 | 0.73 | DRD4 (0.54) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL7975118 | 0.72 | DRD4 (0.59) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL6042349 | 0.72 | SIGMAR1 (0.59) | DRD4DRD3DRD2HTTHTR1A | |
| SCHEMBL4030523 | 0.72 | HDAC4 (0.61) | DRD4DRD3DRD2HTTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | DRD4 4147/4885DRD3 3960/4885DRD2 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.